Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trialResearch Published on 2023-02-182024-09-05 Journal: Respiratory Research [Category] update2024, [키워드] ARDS COVID-19 Inflammation prostacyclin therapy [DOI] 10.1186/s12931-023-02346-0 PMC 바로가기 [Article Type] Research
Evaluation of Continuous Inhaled Epoprostenol in the Treatment of Acute Respiratory Distress Syndrome, Including Patients With SARS-CoV-2 InfectionArticle Published on 2022-10-012023-07-07 Journal: The Annals of Pharmacotherapy [Category] COVID19(2023년), [키워드] ARDS Epoprostenol Inhaled prostacyclin pulmonary vasodilator. SARS-CoV-2 [DOI] 10.1177/10600280211069182
Perinatal Management and Long-Term Follow-up of a Primipara With Severe Pulmonary Arterial Hypertension Associated With Systemic Lupus ErythematosusCase Reports Published on 2022-08-012023-06-24 Journal: Journal of cardiothoracic and vascular anesthesia [Category] 신종인플루엔자, [키워드] Cesarean section perinatal management prostacyclin pulmonary arterial hypertension systemic lupus erythematosus [DOI] 10.1053/j.jvca.2021.06.003 [Article Type] Case Reports
Characterization of prostanoids response to Bordetella pertussis antigen BscF and Tdap in LPS-challenged monocytesArticle Published on 2022-07-312024-09-02 Journal: Prostaglandins, Leukotrienes and Essential Fatty Acids [Category] 백일해, 파상풍, [키워드] Bordetella pertussis lipids prostacyclin prostaglandin Prostanoid Vaccine PMC 바로가기
The effect of prostacyclin infusion on markers of endothelial activation and damage in mechanically ventilated patients with SARS-CoV-2 infectionSARS-CoV-2 감염이 있는 기계 환기 환자의 내피 활성화 및 손상 마커에 대한 프로스타사이클린 주입의 효과Randomized Controlled Trial Published on 2022-06-012022-09-11 Journal: Journal of critical care [Category] COVID19(2023년), SARS, 바이오마커, 임상, [키워드] Activation Adult patients baseline Biomarker Biomarkers blood sample Blood samples CD40L change changes in collected COVID-19 damage decrease endothelial Endothelium glycocalyx groups marker mechanically ventilated mechanically ventilated patient mechanically ventilated patients median medians not differ Organ failure P-selectin Patient pilot study Placebo placebo group plasma Plasma levels prostacyclin protective effect Randomized Randomized controlled trial reduction in SARS-CoV-2 SARS-COV-2 infection selectin significantly syndecan Syndecan-1 the placebo group thrombomodulin with COVID-19 [DOI] 10.1016/j.jcrc.2022.154010 PMC 바로가기 [Article Type] Randomized Controlled Trial
Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized Clinical TrialRandomized Controlled Trial Published on 2022-02-012022-10-05 Journal: American Journal of Respiratory and Critical Care [Category] 임상, 진단, [키워드] 28-day mortality 95% CI 95% confidence interval acute respiratory syndrome analyses clinical conducted coronavirus coronavirus disease COVID-19 days alive determine endotheliopathy EudraCT groups implicated incidence infected with SARS-CoV-2 measurement mechanical ventilation mechanically ventilated patient median medians Mortality multicenter outcome Patient Placebo plasma point estimates prostacyclin Randomized randomized clinical trial reduction in Registered required risk SARS-CoV-2 secondary outcome Serious Adverse Event thrombomodulin Trial trials with COVID-19 [DOI] 10.1164/rccm.202108-1855OC PMC 바로가기 [Article Type] Randomized Controlled Trial
Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature reviewReview article Published on 2022-02-012022-10-05 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] 치료법, 치료제, [키워드] acute respiratory distress antagonists antiviral property Apoptosis appear ARDS Blood blood pressure bosentan Combination COVID-19 COVID-19 associated ARDS database decrease Deterioration drug Endothelin Endothelin receptor antagonists Epoprostenol Google Scholar help IMPROVE Infection inhibit inhibitors investigated literature lung Lung epithelial cells lung lesion Meta-analysis oedema Oxygenation PAH Patient PDE-5 inhibitors prostacyclin pulmonary arterial hypertension pulmonary artery Randomized controlled trials receptor reduce Respiratory function Result Riociguat Severe case severe SARS-CoV-2 syndrome synergism targeted therapy therapy Treatment ventilation/perfusion [DOI] 10.1016/j.biopha.2021.112592 [Article Type] Review article
Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationaleCommentary Published on 2021-09-162022-10-31 Journal: The Egyptian Heart Journal [Category] COVID-19, [키워드] acute respiratory distress Affect alleviate analogue anti-inflammatory effect ARDS COVID-19 demonstrated drug Effect Epoprostenol expected forms high mortality rate hospitalized patient hypertension hypoxia IMPROVE increase Infection Inhaled intravenous life-threatening management Meta-analysis nitric oxide Oxygenation PaO2 paO2/fiO2 parenteral administration Patient pharmacological prostacyclin pulmonary artery pressure Randomized controlled trial reduced Research SARS CoV-2 severe COVID-19 patients syndrome therapy treat Treatment [DOI] 10.1186/s43044-021-00208-y PMC 바로가기 [Article Type] Commentary
COVID-19 Associated Hypercoagulability: Manifestations, Mechanisms, and ManagementArticle Published on 2021-04-022023-06-16 Journal: Shock (Augusta, Ga.) [Category] MERS, [키워드] a disintegrin and metalloproteinase with thrombospondin type 1 motif member 13 ADAMTS13 CFT clot formation time Coagulation coronavirus coronavirus disease-2019 COVID-19 ECMO Embolism extracorporeal membrane oxygenation ICU IL intensive care unit interleukin Jak Janus kinase k kinetic time MA MAPK maximum amplitude maximum clot firmness MCF mitogen-activated protein kinase PAI-1 PGI2 Plasminogen activator inhibitor-1 prostacyclin SARS-CoV-2 severe acute respiratory syndrome coronavirus-2 TEG TEM thromboelastography Thromboelastometry thrombosis TNF tumor necrosis factor ultra-large von Willebrand factor ULVWF Venous Thromboembolism VTE [DOI] 10.1097/SHK.0000000000001660 PMC 바로가기
The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial인공호흡기를 사용하는 COVID-19 환자에서 위약과 비교하여 72시간 동안 1ng/kg/min 용량의 프로스타사이클린(일로프로스트) 주입 효과: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-08-262022-08-13 Journal: Trials [Category] MERS, 임상, [키워드] (Iloprost (normal saline) 1:1 Acute coronary syndrome Adult patient Adult patients age anticipated Biomarker bleeding blinded Blinding block can not Capital Capital Region capture Clinicians comparator concealed conducted Confirmed Confirmed COVID-19 infection Consent coronary syndrome COVID-19 COVID-19 infection COVID-19 patients criteria Day defined Denmark dissemination dose element endothelial endotheliopathy EudraCT exclusion criteria exploratory facilitate FIVE heart failure Hvidovre Hospital hypersensitivity Iloprost intensive care unit intensive care units investigators Local mechanical ventilation mechanically ventilated mechanically ventilated COVID-19 patients mechanically ventilated patient multicenter normal saline number objective outcome parallel group participant Patient patients performed Placebo Pregnancy primary endpoint prostacyclin protocol randomisation randomised Randomized Randomized controlled trial recruitment REDCap Region Sample size sequence statisticians status stratified Study protocol Suspected thrombomodulin total sample size Trial Urine website Withdrawal [DOI] 10.1186/s13063-020-04696-2 PMC 바로가기 [Article Type] Letter